Risk factors for TA-TMA by univariate regression
| . | Odds ratio . | P . | 95% CI . |
|---|---|---|---|
| Age ≥10 y | 3.65 | .03 | 1.13-11.8 |
| Non-White | 2.19 | .14 | 0.77-6.25 |
| HLA mismatched (≤9 of 10) | 1.99 | .20 | 0.69-5.75 |
| CMV seropositive recipient | 2.89 | .08 | 0.90-9.30 |
| Conditioning | |||
| RIC/NMA | 1 | ||
| Non-TBI MAC | 2.71 | .35 | 0.33-22.1 |
| TBI MAC | 9.00 | .05 | 1.04-77.6 |
| Diagnosis | |||
| Malignant | 1 | — | — |
| Nonmalignant other than SAA | — | — | — |
| SAA | 3.00 | .12 | 0.76-11.9 |
| Pre-HSCT CNI exposure | 2.29 | .18 | 0.69-7.55 |
| . | Odds ratio . | P . | 95% CI . |
|---|---|---|---|
| Age ≥10 y | 3.65 | .03 | 1.13-11.8 |
| Non-White | 2.19 | .14 | 0.77-6.25 |
| HLA mismatched (≤9 of 10) | 1.99 | .20 | 0.69-5.75 |
| CMV seropositive recipient | 2.89 | .08 | 0.90-9.30 |
| Conditioning | |||
| RIC/NMA | 1 | ||
| Non-TBI MAC | 2.71 | .35 | 0.33-22.1 |
| TBI MAC | 9.00 | .05 | 1.04-77.6 |
| Diagnosis | |||
| Malignant | 1 | — | — |
| Nonmalignant other than SAA | — | — | — |
| SAA | 3.00 | .12 | 0.76-11.9 |
| Pre-HSCT CNI exposure | 2.29 | .18 | 0.69-7.55 |